Following three intense days of competition in San Francisco, the annual Startup Battlefield at Disrupt 2026 has concluded with the crowning of a new champion. Out of 200 initial hopefuls, 20 standout companies were selected to present live demonstrations before panels of prominent venture capitalists and technology leaders. The rigorous competition challenges founders to showcase their groundbreaking innovations for a chance to win the coveted Startup Battlefield Cup and a $100,000 grand prize.

Following extensive deliberations by the judging panels, five finalists ultimately advanced to the final stage: Apate, Flox Intelligence, Intero Biosystems, Industrial Next, and Satlyt. These finalists pitched their enterprises to a high-profile final panel featuring veteran investors from prominent venture capital firms.

Ultimately, Denver-based Intero Biosystems secured the top honor. Co-founded by Charlie Childs and Madeline Eiken as a spinout from the University of Michigan, the company specializes in cultivating one-millimeter human intestinal organoids. These lab-grown tissues accurately simulate human gut biology, providing researchers with a sophisticated alternative method for evaluating how pharmaceutical drugs, chemicals, and food compounds interact with the human body prior to human clinical trials. Their flagship product, GastroScreen, is marketed directly to biotech, pharmaceutical, and consumer goods companies.

Meanwhile, Australian cybersecurity startup Apate claimed the runner-up position. Founded by Dali Kaafar, Apate deploys sophisticated artificial intelligence agents designed to impersonate potential targets, actively engaging with scammers by answering fraudulent calls, responding to phishing messages, and infiltrating malicious networks to disrupt cybercriminal operations.

Key Takeaways

• Intero Biosystems won the Disrupt 2026 Startup Battlefield, securing the $100,000 grand prize and the championship cup.
• The winning startup develops lab-grown human intestinal organoids used by pharmaceutical and biotech companies for pre-clinical testing.
• Australian cybersecurity firm Apate finished as the runner-up with its AI-powered fraud-baiting technology.

Editor’s Analysis & Impact

The victory of Intero Biosystems at Disrupt 2026 highlights a broader, accelerating trend toward biotechnology and organoid research as ethical, highly accurate alternatives to traditional animal testing. By bridging the gap between computational models and human clinical trials, organoid technology is poised to significantly accelerate drug discovery while lowering R&D costs for pharmaceutical giants. Concurrently, the strong placement of Apate underscores the urgent market demand for offensive cybersecurity solutions that utilize artificial intelligence to combat rising global scam and phishing epidemics. These winning companies represent the vanguard of deep tech, where rigorous scientific research and automated defense systems attract substantial venture capital interest, ultimately paving the way for lucrative future exits in increasingly digitized global markets.

Frequently Asked Questions

Q: What is Intero Biosystems?
A: Intero Biosystems is a Denver-based biotechnology startup that develops lab-grown human intestinal organoids to test the efficacy and safety of drugs, chemicals, and food compounds before human trials.

Q: What did the winner of Startup Battlefield 2026 receive?
A: The winner took home the Startup Battlefield Cup and a cash prize of $100,000.

Q: How does the runner-up, Apate, function?
A: Apate deploys thousands of AI agents designed to impersonate potential victims, engaging with fraudsters through scam calls, phishing emails, and fraudulent messaging to disrupt their operations and gather intelligence.